triggering receptor expressed on myeloid cells like 1Genealiases: GLTL1825 · PRO3438 · TLT-1 · TLT1 · dJ238O23.3
Q-omics provides the consensus-scored TREML1 profile across patient tissues and cancer cell-line models. TREML1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TREML1 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, TREML1 RNA expression shows 15,017 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, KIRC, and GBM as cancer lineages where TREML1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TREML1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TREML1 survival associations across molecular data types. TREML1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TREML1 RNA expression–survival associations across cancer types. High TREML1 expression shows unfavorable associations in KIRC and OV, but favorable associations in HNSC, CESC, LUAD and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TREML1 RNA expression.
This table summarizes TREML1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TREML1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TREML1 shows lower tumor expression in LUAD and LUSC and higher tumor expression in KIRC, HNSC, KIRP and STAD. The KIRC box plot shows higher TREML1 RNA expression in tumor versus normal tissue (log2 FC = +0.730, t-test p < 0.001).
This table shows molecular features associated with TREML1 in patient tissues and cancer cell lines. In patient samples, TREML1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TREML1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and LARGE_INTESTINE.
